Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized Antiplatelet Therapy After NeoVas Stent Implantation
NCT04995159Not yet recruiting
- Sponsor
- Lepu Medical
- Start
- Sep 2021
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of clopidogrel in coronary heart disease (CHD) (2 cohorts), sponsored by Lepu Medical. Primary endpoint: Net Adverse Clinical Event at 3 years. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
clopidogrel
03
Conditions
coronary heart disease (CHD)
Beyond the preview
Go deeper on NCT04995159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04995159.